Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2022 Mar 26;22(1):329.
doi: 10.1186/s12885-022-09448-w.

Recurrence and prognosis in intrahepatic cholangiocarcinoma patients with different etiology after radical resection: a multi-institutional study

Qi Li  1 , Chen Chen  1 , Jingbo Su  1 , Yinghe Qiu  2 , Hong Wu  3 , Tianqiang Song  4 , Xianhai Mao  5 , Yu He  6 , Zhangjun Cheng  7 , Jingdong Li  8 , Wenlong Zhai  9 , Dong Zhang  1 , Zhimin Geng  10 , Zhaohui Tang  11
Affiliations
Multicenter Study

Recurrence and prognosis in intrahepatic cholangiocarcinoma patients with different etiology after radical resection: a multi-institutional study

Qi Li et al. BMC Cancer. .

Abstract

Objective: We aimed to evaluate the prognosis and adjuvant chemotherapy (ACT) in intrahepatic cholangiocarcinoma (ICC) patients with different etiology after radical resection.

Methods: A total of 448 patients with ICC who underwent radical resection between 2010 and 2018 at ten Chinese tertiary hospitals were analyzed in the study. These patients were divided into conventional ICC (Con-ICC, n = 261, 58.2%), hepatitis B virus ICC (HBV-ICC, n = 102, 22.8%) and hepatolithiasis (Stone-ICC, n = 85,19.0%) subtypes according to different etiology. Propensity score matching (PSM) was conducted to mitigate the baseline differences between Con-ICC and HBV-ICC, Con-ICC and Stone-ICC, HBV-ICC and Stone-ICC subtypes.

Results: Univariate and multivariate analysis showed that different etiology was a prognostic factor for overall survival and relapse-free survival, and different etiology was an independent risk factor for overall survival in ICC patients, respectively (P < 0.05). In addition, there was a statistical difference for overall survival in early recurrence patients among the three etiological subtypes (P < 0.05). After PSM, the overall survival of patients with Stone-ICC was worse than those of Con-ICC and HBV-ICC subtypes (P < 0.05), while the relapse-free survival of patients with Stone-ICC was equivalent to patients with Con-ICC and HBV-ICC (P > 0.05). In Stone-ICC patients, the median overall survival was 16.0 months and 29.7 months, and the median relapse-free survival was 9.0 months and 20.0 months for non-ACT and ACT patients, respectively (P < 0.05).

Conclusion: The prognosis of Stone-ICC patients was significantly worse than those of Con-ICC and HBV-ICC patients. Interestingly, postoperative adjuvant chemotherapy can improve the prognosis of Stone-ICC patients effectively.

Keywords: Hepatitis B virus; Hepatolithiasis; Intrahepatic cholangiocarcinoma; Prognosis; Recurrence.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Comparison of overall survival and relapse-free survival after radical resection between conventional ICC and HBV-ICC (A and B), between conventional ICC and Stone-ICC (C and D), and between HBV-ICC and Stone-ICC (E and F) before PSM
Fig. 2
Fig. 2
Comparison of overall survival and relapse-free survival after radical resection between conventional ICC and HBV-ICC (A and B), between conventional ICC and Stone-ICC (C and D), and between HBV-ICC and Stone-ICC (E and F) after PSM
Fig. 3
Fig. 3
Comparison of overall recurrence ratio (A), recurrence time ≤ 1 year and > 1 year (B), and overall survival time with recurrence time ≤ 1 year (C) and overall survival time with recurrence time > 1 year after radical resection for conventional ICC, HBV-ICC and Stone-ICC
Fig. 4
Fig. 4
Comparison of overall survival and relapse-free survival in adjuvant chemotherapy after radical resection between conventional ICC and HBV-ICC (A and B), between conventional ICC and Stone-ICC (C and D), and between HBV-ICC and Stone-ICC (E and F)
See this image and copyright information in PMC

References

    1. Massarweh NN, El-Serag HB. Epidemiology of hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Cancer Control. 2017;24(3):1145164509. doi: 10.1177/1073274817729245. - DOI - PMC - PubMed
    1. Moeini A, Sia D, Bardeesy N, et al. Molecular pathogenesis and targeted therapies for intrahepatic cholangiocarcinoma. Clin Cancer Res. 2016;22(2):291–300. doi: 10.1158/1078-0432.CCR-14-3296. - DOI - PubMed
    1. Razumilava N, Gores GJ. Cholangiocarcinoma. Lancet. 2014;383(9935):2168–2179. doi: 10.1016/S0140-6736(13)61903-0. - DOI - PMC - PubMed
    1. Sirica AE, Gores GJ, Groopman JD, et al. Intrahepatic cholangiocarcinoma: continuing challenges and translational advances. Hepatology. 2019;69(4):1803–1815. doi: 10.1002/hep.30289. - DOI - PMC - PubMed
    1. Amini N, Ejaz A, Spolverato G, et al. Temporal trends in liver-directed therapy of patients with intrahepatic cholangiocarcinoma in the United States: a population-based analysis. J Surg Oncol. 2014;110(2):163–170. doi: 10.1002/jso.23605. - DOI - PubMed

Publication types